Elicio Therapeutics Inc. Net Assets
Elicio Therapeutics Inc. net assets. Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has net assets worth $7.94 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.33 Million) and total liabilities ($23.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ELTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.94 Million |
| % of Total Assets | 25.33% |
| Annual Growth Rate | -7.06% |
| 5-Year Change | -97.99% |
| 10-Year Change | N/A |
| Growth Volatility | 177.96 |
Net Assets of Elicio Therapeutics Inc. (2012–2025)
Net assets of Elicio Therapeutics Inc. from 2012 to 2025. This chart illustrates how Elicio Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See Elicio Therapeutics Inc. (ELTX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual net assets of Elicio Therapeutics Inc. from 2012 to 2025. For live market cap and overall valuation, see Elicio Therapeutics Inc. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.64 Million | +114.46% |
| 2024-12-31 | $-11.31 Million | -199.46% |
| 2023-12-31 | $11.37 Million | +27.57% |
| 2022-12-31 | $8.91 Million | -89.06% |
| 2021-12-31 | $81.51 Million | +190.11% |
| 2020-12-31 | $-90.45 Million | -386.65% |
| 2019-12-31 | $-18.59 Million | -198.28% |
| 2018-12-31 | $18.91 Million | +324.05% |
| 2013-12-31 | $4.46 Million | +5.22% |
| 2012-12-31 | $4.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elicio Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13806.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Elicio Therapeutics Inc. Net Assets Breakdown (December 2025)
Elicio Therapeutics Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $178.00K | 10.88% |
| Other Comprehensive Income | $-127.00K | -7.76% |
| Other Components | $235.26 Million | 14380.01% |
| Total Equity | $1.64 Million | 100.00% |
Elicio Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Elicio Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CVC Technologies
TWO:4744
|
$43.24 Million |
|
Altustfi
WAR:ALI
|
$43.25 Million |
|
Vinyl Group Ltd
AU:VNL
|
$43.27 Million |
|
Chorokbaem Media Co. Ltd
KQ:047820
|
$43.28 Million |
|
Farm Pride Foods Ltd
AU:FRM
|
$43.23 Million |
|
MACH7 Technologies Ltd
AU:M7T
|
$43.23 Million |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
$43.21 Million |
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
$43.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elicio Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -11,312,000 to 1,636,000, a change of 12,948,000.
- Net loss of 39,571,000 reduced equity.
- New share issuances of 25,387,000 increased equity.
- Other comprehensive income increased equity by 48,000.
- Other factors increased equity by 27,084,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.57 Million | -2418.77% |
| Share Issuances | $25.39 Million | +1551.77% |
| Other Comprehensive Income | $48.00K | +2.93% |
| Other Changes | $27.08 Million | +1655.5% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Elicio Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 15.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $279.52 | $1.65 | x |
| 2013-12-31 | $382.83 | $1.65 | x |
| 2018-12-31 | $6.41 | $1.65 | x |
| 2019-12-31 | $-2.28 | $1.65 | x |
| 2020-12-31 | $-11.10 | $1.65 | x |
| 2021-12-31 | $25.47 | $1.65 | x |
| 2022-12-31 | $2.88 | $1.65 | x |
| 2023-12-31 | $2.25 | $1.65 | x |
| 2024-12-31 | $-0.93 | $1.65 | x |
| 2025-12-31 | $0.11 | $1.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elicio Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2418.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 15.81x
- Recent ROE (-2418.77%) is below the historical average (-313.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 17.96% | 4.21% | 0.66x | 6.45x | $136.24K |
| 2013 | 26.99% | 9.61% | 0.59x | 4.72x | $397.95K |
| 2018 | -105.89% | -497.02% | 0.15x | 1.41x | $-21.92 Million |
| 2019 | 0.00% | -2734.23% | 0.13x | 0.00x | $-38.80 Million |
| 2020 | 0.00% | -2781.49% | 0.06x | 0.00x | $-71.06 Million |
| 2021 | -32.39% | -93.25% | 0.29x | 1.18x | $-34.55 Million |
| 2022 | -316.41% | 0.00% | 0.00x | 2.54x | $-29.10 Million |
| 2023 | -309.46% | 0.00% | 0.00x | 2.39x | $-36.33 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.77 Million |
| 2025 | -2418.77% | 0.00% | 0.00x | 15.81x | $-39.73 Million |
Industry Comparison
This section compares Elicio Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $141,999,647
- Average return on equity (ROE) among peers: -27.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elicio Therapeutics Inc. (ELTX) | $7.94 Million | 17.96% | 2.95x | $43.23 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $29.39 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $145.25 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $17.12 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $736.95 Million |
| ABVC Biopharma Inc (ABVC) | $87.34K | 2.91% | 0.03x | $27.19 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.59 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $2.84 Billion |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more